From a total of 1053 patients diagnosed with NSCLC, 113 (20.0%) had Nrf2-activating MU in the LUAD subtype and 88 (18.0%) did so in the LUSC subtype (Fig. 4C). This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.